Kazunari Tominaga

Kazunari Tominaga

Auto-generated profile, based on publicly available information

Kazunari Tominaga

Department of Gastroenterology, Osaka City University Graduate School of Medicine, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in American Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
YNYasuaki Nagami
Yasuaki Nagami
KTKazunari Tominaga
Kazunari Tominaga
HMHirohisa Machida
Hirohisa Machida
MNMasami Nakatani
Masami Nakatani
NKNatsuhiko Kameda
Natsuhiko Kameda
TATetsuo Arakawa
Tetsuo Arakawa
The usefulness of non-magnifying endoscopy with narrow-band imaging (NBI; NM-NBI) in the screening of early esophageal squamous cell carcinoma (SCC) and high-grade intraepithelial neoplasia (HGIN) remains unclear. Here, we aimed to compare NM-NBI and chromoendoscopy with iodine staining (CE-Iodine) in terms of the diagnostic performance, and to evaluate the usefulness of NM-NBI in detecting early esophageal SCC. We prospectively enrolled 202 consecutive patients (male/female=180/22; median age, 67 years) with high-risk factors for esophageal SCC. All patients received endoscopic examination with NM-NBI and CE-Iodine to screen for early esophageal SCC or HGIN. We conducted the examinations sequentially, and calculated the accuracy, sensitivity, and specificity through a per-lesion-based analysis. A propensity score matching analysis was performed to reduce the effects of selection bias, and we compared the respective outcomes according to NM-NBI and CE-Iodine after matching. The accuracy, sensitivity, and specificity of NM-NBI were 77.0, 88.3, and 75.2%, respectively, and those for unstained areas by CE-Iodine were 68.0, 94.2, and 64.0, respectively. The accuracy and specificity of NM-NBI were superior to those of CE-Iodine (P=0.03 and P=0.01, respectively). However, the sensitivity did not significantly differ between NM-NBI and CE-Iodine (P=0.67). The accuracy and specificity of NM-NBI before matching were superior to those of CE-Iodine after matching (P=0.04 and P=0.03). NM-NBI was useful and reliable for the diagnosis of esophageal SCC and can be a promising screening strategy for early esophageal SCC.

15 November 2011 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
KTKazunari Tominaga
Kazunari Tominaga
RIRyuichi Iwakiri
Ryuichi Iwakiri
KFKazuma Fujimoto
Kazuma Fujimoto
YFYasuhiro Fujiwara
Yasuhiro Fujiwara
MTMio Tanaka
Mio Tanaka
TATetsuo Arakawa
Tetsuo Arakawa

1 January 2011 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
KTK. Tominaga
K. Tominaga
TKT. Kido
T. Kido
MOM. Ochi
M. Ochi
CSC. Sadakane
C. Sadakane
AMA. Mase
A. Mase
TAT. Arakawa
T. Arakawa
The traditional Japanese medicine rikkunshito ameliorates the nitric oxide‐associated delay in gastric emptying. Whether rikkunshito affects gastric motility associated with 5‐hydroxytryptamine (serotonin: 5‐HT) receptors or dopamine receptors is unknown. We examined the effects of rikkunshito on the delay in gastric emptying induced by 5‐HT or dopamine using the phenol red method in male Wistar rats. 5‐HT (0.01–1.0 mg kg−1, i.p.) dose dependently delayed gastric emptying, similar to the effect of the 5‐HT3 receptor agonist 1‐(3‐chlorophenyl) biguanide (0.01–1.0 mg kg−1, i.p.). Dopamine also dose dependently delayed gastric emptying. The 5‐HT3 receptor antagonist ondansetron (0.04–4.0 mg kg−1) and rikkunshito (125–500 mg kg−1) significantly suppressed the delay in gastric emptying caused by 5‐HT or 1‐(3‐chlorophenyl) biguanide. Hesperidin (the most active ingredient in rikkunshito) suppressed the 5‐HT‐induced delayed gastric emptying in a dose‐dependent manner, the maximum effect of which was similar to that of ondansetron (0.4 mg kg−1). The improvement obtained by rikkunshito or ondansetron in delaying gastric emptying was completely blocked by pretreatment with atropine. Rikkunshito appears to improve delay in gastric emptying via the antagonistic action of the 5‐HT3 receptor pathway.

1 August 2005 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
RAReiko Ashida
Reiko Ashida
KTKazunari Tominaga
Kazunari Tominaga
ESEiji Sasaki
Eiji Sasaki
TWToshio Watanabe
Toshio Watanabe
YFYasuhiro Fujiwara
Yasuhiro Fujiwara
TATetsuo Arakawa
Tetsuo Arakawa
Activator protein-1 (AP-1) is a transcription factor that consists of either a Jun-Jun homodimer or a Jun-Fos heterodimer. AP-1 regulates the expression of multiple genes essential for cell proliferation, differentiation and apoptosis. Numerous reports suggest that AP-1 plays an important role in various human diseases. Among them, the roles relating to human cancers have been strongly suggested for a long time. In human cancers, colorectal cancer is still a leading cause of morbidity and mortality in the world. Since there are some reports about the role of AP-1 in colorectal cancer response to a number of stimuli, such as cytokines and growth factors, and oncogenic transformation, therapeutic inhibition of AP-1 activity has attracted considerable interest. Here, we demonstrate the biological properties of AP-1 and its role in colorectal cancer, and discuss a possibility of an AP-1 inhibitor, an adenovirus dominant-negative mutant of c-Jun, as a therapeutic a gent for gene therapy.

16 March 2013 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
KTKazunari Tominaga
Kazunari Tominaga
TATetsuo Arakawa
Tetsuo Arakawa
Treatment with kampo, the Japanese traditional medicine, is a form of pharmacological therapy that combines modern Western and traditional Asian medical practices. In Japan, various traditional medicines are often combined with Western medicines and prescribed for patients with diseases such as gastroesophageal reflux disease, functional dyspepsia, chronic gastritis, irritable bowel syndrome, and post-operative ileus. Based on numerous past observations, Japanese traditional medicines are thought to be particularly useful in the treatment of medically unexplained physical symptoms such as nausea, abdominal discomfort, and anorexia. However, the detailed mechanism by which they mediate their pharmacological action is yet unknown. In addition, the clinical evidence to support their use is insufficient. This review focuses on the basic evidence of the pharmacological action and the clinical efficacies of kampo medicines accumulated over several past decades. In addition, we introduce both the current novel insights into kampo medicines and the therapeutic approach employed when they are used to treat various disorders of the gastrointestinal tract.

6 September 2002 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
KTKazunari Tominaga
Kazunari Tominaga
KHKazuhide Higuchi
Kazuhide Higuchi
NHNorio Hamasaki
Norio Hamasaki
MHMasaki Hamaguchi
Masaki Hamaguchi
TTTakashi Takashima
Takashi Takashima
TATetsuo Arakawa
Tetsuo Arakawa
Previously purified and isolated compounds of novel alkyl methyl quinolone alkaloids (AM quinolones) from Gosyuyu (Wu-Chu-Yu), a Chinese herbal medicine, have a strong and highly selective antibacterial activity against Helicobacter pyloriin vitro. To clarify the antibacterial mechanism(s) of AM quinolones, we examined the effects of AM quinolones on respiration of H. pylori in vitro. One week after treatment with AM quinolones alone (2, 10 or 20 mg/kg/day, orally) or combinations of AM quinolones and omeprazole (30 mg/kg/day) for H. pylori (1 × 108 cfu)-infected Mongolian gerbils, we checked viable H. pylori and myeloperoxidase (MPO) activity in the gastric tissues. AM quinolones decreased the number of H. pylori and inhibited H. pylori respiration in a dose-dependent manner. AM quinolones decreased the number of viable H. pylori (AM quinolones alone: 46.0 ± 22.6 × 104, 17.3 ± 4.9 × 104 and 8.1 ± 6.6 × 104 cfu/stomach, respectively; and combinations of AM quinolones and omeprazole: 8.0 ± 5.6 × 104, 4.2 ± 2.5 × 104 and 5.5 ± 2.7 × 104 cfu/stomach) compared with the vehicle-treated group (control: 359.9 ± 180.3 × 104 cfu/stomach). AM quinolones significantly decreased MPO activity of H. pylori-inoculated gastric tissues. These findings suggest that AM quinolones have a potent antibacterial effect against H. pylori through respiratory inhibition, and reduced bacterial growth in vivo. AM quinolones might be novel therapeutic agents for H. pylori eradication.